Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Inclusion Criteria:

- Completed participation or discontinued due to lack of efficacy at week 5 or later in
either Trial 31-10-272 or 31-10-273

- Written ICF obtained from a legally acceptable representative & informed assent at
Baseline as applicable by trial center's IRB/IEC

- The subject, designated guardian(s) or caregiver(s) are able to comprehend and
satisfactorily comply with the protocol requirements, as evaluated by the
investigator.

Exclusion Criteria:

- The subject experienced AEs during the double-blind trial (31-10-272 or 31-10-273)
that would, in the investigator's judgment, preclude further exposure to
aripiprazole.

- The subject had protocol violations during the double-blind trial considered major in
the judgment of the investigator which would deem the subject a poor candidate for
the trial

- A positive drug screen at baseline for cocaine, alcohol or other drugs of abuse which
will result in early termination at Week 1

- Sexually active patients not using 2 approved methods of contraception; breastfeeding
or pregnant.

- Risk of committing suicide

- Body weight lower than 16 kg

- Abnormal laboratory test results, vital signs and ECG results